Selected article for: "clinical development and vaccine development"

Author: Andrea Torneri; Pieter Jules Karel Libin; Joris Vanderlocht; Anne-Mieke Vandamme; Johan Neyts; Niel Hens
Title: A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
  • Document date: 2020_3_20
  • ID: 9sr5b44k_5
    Snippet: This probability is computed, at a precise time point, as the product of two components: the 47 infectiousness measure, ν(t), which quantifies the level of infectiousness over time, and the total 48 amount of infectivity q, i.e. the number of infections over the contact rate. 6 The function ν(t) is 49 defined over the exposed and infectious period, or analogously over the incubation and symptomatic 50 period, along which it integrates to one. T.....
    Document: This probability is computed, at a precise time point, as the product of two components: the 47 infectiousness measure, ν(t), which quantifies the level of infectiousness over time, and the total 48 amount of infectivity q, i.e. the number of infections over the contact rate. 6 The function ν(t) is 49 defined over the exposed and infectious period, or analogously over the incubation and symptomatic 50 period, along which it integrates to one. This function is scaled to have a similar shape among 51 different infectives, based on their lengths of exposed and infectious period. According to this 52 framework, an infectious individual makes effective contacts at a rate, r(t) given by:

    Search related documents:
    Co phrase search for related documents